Ocugen, Inc. — Director's Dealing 2014

Dec 3, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2014-12-02

Reporting Person: JOHNSON JOHN (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.13	2023-12-10	Common Stock (9255)		Direct

Footnotes

F1: This option vests over four years following November 13, 2013, with 25% of the shares vesting upon completion of each year of continuous service.

F2: Reflects a 10.804-to-1 reverse stock split effected on November 14, 2014.